BrightGene adjusts stakes in GeekGene and Olay Bio

BrightGene Bio-Medical Technology (SSE:688166) has approved a RMB 50 million capital increase in Suzhou GeekGene Biotechnology Co., Ltd. This investment increases BrightGene's stake in GeekGene from 4.0816% to 12.8015%. The board also approved the convening of a second extraordinary general meeting on December 1, 2025, to seek shareholder approval for this transaction.

Concurrently, BrightGene's board has decided to waive its pre-emptive right in the capital increase of its associate, Shenzhen Olay Bio-Medical Technology Co., Ltd. Olay Bio is raising RMB 80 million, with Suzhou Hongbo Phase II Investment Partnership (Limited Partnership) investing RMB 25 million and other investors contributing RMB 55 million. This decision will result in BrightGene's shareholding in Olay Bio decreasing from 30.1664% to 24.420458%.

The waiver of pre-emptive rights in Olay Bio constitutes a related-party transaction, as BrightGene's controlling shareholder, Yuan Jiandong, serves on the investment decision committee of Hongbo Phase II. This transaction has been reviewed and approved by the independent directors and the board, which deemed it fair and in the best interest of the company and its shareholders, with no material adverse effect on BrightGene's financials or operations.